SEC Form 4 · accession 0001209191-15-076817
GYRE THERAPEUTICS, INC. · GYRE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Edwin Madison
Officer — Chief Scientific Officer
Period of report
Oct 22, 2015
Accepted (ET)
Oct 26, 2015 · 7:10 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001124105
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $4.40 | Oct 22, 2015 | A | 71,428 | A | — | Oct 22, 2025 | Common Stock | 71,428 | 71,428 | D |
| Stock Option (Right to Buy)F1,F2 | $4.40 | Oct 22, 2015 | A | 58,572 | A | — | Oct 22, 2025 | Common Stock | 58,572 | 58,572 | D |
Explanation of responses
- F1Award vests monthly over four (4) years starting September 1, 2015.
- F2This award is subject to shareholder approval of an amendment to the Issuers' 2015 Stock Incentive Plan.